Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Falzone ME, Rheinberger J, Lee B-, Peyear T, Sasset L, Raczkowski AM, et al. Structural basis of Ca-dependent activation and lipid transport by a TMEM16 scramblase. Elife. 2019;8.

DeSimone RA, Ong SJ, Crowley KM, Vasovic LV, Senaldi E, Kessler DA, et al. Hereditary elliptocytosis of donor red blood cell unit detected during Coombs crossmatch. Transfusion. 2019;59(2):446-447.

Gross MD, Awamlh BA, Shoag JE, Mauer E, Banerjee S, Margolis DJ, et al. Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. BMJ Surg Interv Health Technol. 2019;1(1):e000010.

Zennami K, Choi SM, Liao R, Li Y, Dinalankara W, Marchionni L, et al. PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res. 2019;17(2):618-627.

Orleans RA, Magro CM, Varghese GI. A subcutaneous nodule on the mid back. JAAD Case Rep. 2019;5(3):252-254.

Penchev VR, Chang Y-, Begum A, Ewachiw T, Gocke C, Li J, et al. Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Mol Cancer Res. 2019;17(4):929-936.

Choi S, Wang D, Chen X, Tang LH, Verma A, Chen Z, et al. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression. Mol Cancer. 2019;18(1):92.

Crowe EP, DeSimone RA. Transfusion support and alternatives for Jehovah's Witness patients. Curr Opin Hematol. 2019;26(6):473-479.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, et al. Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. J Natl Compr Canc Netw. 2019;17(3):194-200.

Zhu H, Wang M, Dong Y, Hu H, Zhang Q, Qiao C, et al. Detection of non-criteria autoantibodies in women without apparent causes for pregnancy loss. J Clin Lab Anal. 2019;33(9):e22994.